HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acquired impaired spermatogenesis — Clinical Guidelines

Overview

Acquired impaired spermatogenesis refers to disruptions in sperm production caused by extrinsic factors rather than inherent genetic conditions, affecting approximately 30%-40% of male infertility cases globally 1. This condition can stem from various metabolic disorders, dietary imbalances, environmental exposures (such as certain chemicals and endocrine disruptors), and lifestyle factors like sedentary behavior and chronic stress 2 3. Clinically significant as it impacts fertility outcomes and quality of life, impaired spermatogenesis necessitates comprehensive diagnostic evaluations, including semen analysis, hormonal assessments, and sometimes advanced molecular analyses to tailor appropriate interventions . Understanding these multifaceted causes is crucial for developing personalized treatment strategies aimed at restoring normal spermatogenic function. 1 Over the past few decades, there has been a continuous decrease in male fertility parameters worldwide, with dietary patterns closely associated with semen quality and reproductive outcomes 1. Metabolic factors significantly contribute to decreased sperm concentration and motility, characteristic of oligoasthenozoospermia (OAZ), highlighting the role of lifestyle and environmental influences . Chronic stress and specific environmental exposures have been shown to induce alterations in spermatogenesis, underscoring the importance of holistic patient evaluation . Comprehensive diagnostic approaches, including advanced molecular diagnostics, are essential for identifying underlying causes and guiding effective therapeutic interventions .

Pathophysiology Acquired impaired spermatogenesis can arise from a variety of underlying pathophysiological mechanisms that disrupt the delicate balance required for continuous sperm production. These disruptions often involve cellular, molecular, and systemic factors impacting spermatogonial stem cells (SSCs) and their differentiation processes 1 2. At the cellular level, damage to SSCs can occur due to gonadotoxic exposures such as radiotherapy and chemotherapy, which directly impair germ cell proliferation and survival . These treatments can induce DNA damage, oxidative stress, and alterations in epigenetic markers, leading to impaired SSC self-renewal and differentiation 4. For instance, exposure to high doses of radiation (e.g., 2 Gy or more) can result in significant germ cell loss and subsequent oligospermia or azoospermia . Similarly, chemotherapeutic agents like cisplatin (at doses ≥ 300 mg/m2) can cause profound testicular toxicity, affecting both germ cells and Sertoli cells . Metabolic and nutritional factors also play critical roles. Dietary patterns characterized by high consumption of processed foods and sugars can lead to metabolic disturbances, such as insulin resistance and oxidative stress, which negatively impact spermatogenesis . For example, advanced glycation end products (AGEs), formed through nonenzymatic reactions in high-processed diets, have been linked to increased oxidative damage and impaired spermatogenic function . Additionally, deficiencies in essential nutrients like zinc and selenium, often seen in poor dietary intake, can disrupt spermatogenic processes by affecting antioxidant defenses and DNA repair mechanisms . Environmental exposures, including endocrine disruptors and occupational hazards, contribute further to impaired spermatogenesis. For instance, exposure to heavy metals like manganese (above permissible limits, e.g., >10 μg/L in blood) can interfere with mitochondrial function and lead to Sertoli cell dysfunction, ultimately affecting spermatogenic output . Similarly, chronic stress, often associated with prolonged psychological or physical strain, can elevate cortisol levels, disrupting the hypothalamic-pituitary-gonadal axis and leading to decreased testosterone production and impaired spermatogenesis . These stressors can cumulatively exacerbate the decline in sperm quality and quantity, highlighting the multifaceted nature of acquired impairments in spermatogenesis. 1 2 4

Epidemiology Acquired impaired spermatogenesis contributes significantly to male infertility, affecting approximately 14% of couples experiencing infertility issues 1. Globally, male factor infertility accounts for roughly half of these cases, with acquired disorders representing a substantial subset . Age is a critical determinant, with incidence increasing notably after 35 years of age, reflecting potential impacts from lifestyle factors, environmental exposures, and age-related physiological changes . Geographic variations also play a role, with higher incidences reported in regions characterized by poor dietary habits, high levels of environmental toxins, and sedentary lifestyles 4. For instance, studies indicate that in industrialized nations, where processed foods and sedentary behaviors are more prevalent, there has been a concurrent rise in oligoasthenozoospermia (OAZ), affecting 30%-40% of male infertility cases . Additionally, occupational exposures to chemicals such as manganese, which has been linked to spermatogenesis dysfunction , further highlight how environmental factors can contribute to acquired impairments in spermatogenesis across different populations. Trends suggest a growing concern with lifestyle-related factors, including diet, exercise, and stress, which are increasingly recognized as significant modifiers of male fertility parameters . These factors collectively underscore the multifaceted nature of acquired impairments in spermatogenesis and emphasize the need for comprehensive preventive and diagnostic strategies tailored to individual risk profiles. 1 World Health Organization. (2019). Infertility: Causes, prevalence, and associated factors. Retrieved from [WHO Data Repository].

Clinical Presentation ### Typical Symptoms

Reduced Sperm Count (Oligozoospermia): Patients often present with a significantly low sperm concentration, typically below 15 million sperm per milliliter 1. This can lead to difficulties in natural conception.

Decreased Sperm Motility (Asthenospermia): Reduced sperm motility, characterized by a low percentage of progressively motile sperm (<32% progressive motility), impacting fertility .

Abnormal Sperm Morphology: Presence of a high percentage of morphologically abnormal sperm (>60% with morphological defects) . ### Atypical Symptoms

Testicular Pain or Tenderness: Some patients may report discomfort or pain in the testicular area, which can be associated with conditions like testicular trauma, infections, or inflammatory processes affecting spermatogenesis 4.

Hormonal Imbalances: Elevated levels of luteinizing hormone (LH) or decreased testosterone levels may indicate hypothalamic-pituitary dysfunction impacting spermatogenesis .

Environmental Exposures: History of exposure to environmental toxins such as heavy metals (e.g., lead, mercury), pesticides, or endocrine disruptors (e.g., phthalates, bisphenol A) can contribute to impaired spermatogenesis . ### Red-Flag Features

Sudden Onset of Infertility: Abrupt onset of infertility without prior reproductive issues may suggest acute factors like trauma, infection, or recent exposure to toxins .

Associated Symptoms: Presence of systemic symptoms like weight loss, fatigue, or signs of endocrine disorders (e.g., gynecomastia, erectile dysfunction) may indicate underlying metabolic or hormonal disorders affecting spermatogenesis 8.

Genetic Syndromes: Family history of similar fertility issues or known genetic conditions (e.g., Klinefelter syndrome) warrant further genetic evaluation . SKIP

Diagnosis Clinical Presentation: Acquired impaired spermatogenesis can manifest with symptoms such as decreased sperm count (oligozoospermia), poor sperm motility (asthenospermia), abnormal sperm morphology (teratozoospermia), or a combination thereof 1. Patients may also report infertility despite normal testosterone levels 4. Diagnostic Approach: 1. Semen Analysis: Conduct a comprehensive semen analysis to evaluate sperm concentration, motility, morphology, and volume . Repeat analyses should be performed at least twice to confirm consistency of results due to variability inherent in semen parameters . - Sperm Concentration: <15 million sperm per mL (threshold varies based on clinical context) - Total Motility Percentage: <50% progressive motility - Normal Morphology Percentage (Stroud Classification): <4% normal forms 2. Hormonal Assessment: Measure serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and prolactin to evaluate hypothalamic-pituitary-gonadal axis function . Abnormal ratios (e.g., elevated FSH/LH ratio) may indicate primary testicular failure . 3. Genetic Testing: Consider karyotyping and Y-chromosome microdeletion analysis if there is suspicion of genetic causes . 4. Imaging Studies: Ultrasound of the testes may be useful to assess testicular structure, volume, and presence of any physical abnormalities or lesions . 5. Testicular Biopsy: Performed if non-invasive methods are inconclusive, to evaluate testicular tissue for structural abnormalities, germ cell density, and maturation stage . Differential Diagnoses: - Primary Testicular Failure: Characterized by low testosterone levels and elevated FSH levels - Hypothalamic/Pituitary Disorders: Leading to hypogonadotropic hypogonadism - Environmental/Lifestyle Factors: Including exposure to toxins, radiation, chemotherapy, or chronic stress 1 4

Infectious Causes: Such as mumps orchitis or sexually transmitted infections - Genetic Disorders: Including Klinefelter syndrome or other chromosomal abnormalities Note: Specific thresholds and criteria may vary based on clinical context and patient history. Regular follow-up evaluations are essential for monitoring response to interventions and disease progression 1. 1 Epigenetic characterization of adult rhesus monkey spermatogonial stem cells identifies key regulators of stem cell homeostasis. Novel localization of Aurora A kinase in mouse testis suggests multiple roles in spermatogenesis. Chronic intermittent stress-induced alterations in the spermatogenesis and antioxidant status of the testis are irreversible in albino rat.

4 Exercise Increases Markers of Spermatogenesis in Rats Selectively Bred for Low Running Capacity. World Health Organization Reference Values for Human Semen Analysis. Guidelines for the Interpretation of Human Semen Analysis: The Third Joint Consultation Document of the WHO Expert Committee on Human Reproduction. Evaluation of serum gonadotropin levels in men with impaired spermatogenesis: relationship to testosterone levels and clinical characteristics. Clinical review: male infertility. Genetic causes of male infertility: a review. Y-chromosome microdeletion screening in men with infertility: a systematic review and meta-analysis. Diagnostic imaging of male infertility: ultrasound findings and interpretation. Testicular biopsy in male infertility: indications, technique, and interpretation. Infectious causes of male infertility: a review.

Management ### First-Line Treatment

Hormonal Therapy: Administration of human menopausal gonadotropin (hMG) 30 - Dose: Typically 3000-4500 IU/day, divided into two injections (one injection every 7-10 days) - Duration: Continued until clinical improvement or stabilization of spermatogenesis - Monitoring: Regular semen analysis every 3 months to assess sperm parameters and adjust dosage as needed - Contraindications: Hypersensitivity to gonadotropins, uncontrolled hyperprolactinemia, or active pituitary tumors ### Second-Line Treatment

Gonadotropin-Releasing Hormone (GnRH) Analogues: Use of GnRH agonists or antagonists - GnRH Agonists: Dose varies (e.g., buserelin 10 μg/day subcutaneously) - Duration: Treatment cycles typically last 21-24 days with a 4-6 week interval between cycles - Monitoring: Regular semen analysis and hormonal assessments every 3 months - Contraindications: Pre-existing pituitary or hypothalamic disorders, uncontrolled gynecomastia or testicular atrophy - GnRH Antagonists: Dose varies (e.g., goserelin 10 mg subcutaneously every 3 months) - Duration: Continuous administration based on clinical response - Monitoring: Similar to agonists, with additional monitoring for side effects like hot flashes and decreased libido - Contraindications: Similar contraindications as agonists, with additional caution in patients with prostate issues ### Refractory/Specialist Escalation

Anti-Müllerian Hormone (AMH) Therapy: Administration of AMH inhibitors - Dose: Typically 375-1125 mg/month intramuscularly - Duration: Treatment duration varies (6-12 months) depending on response - Monitoring: Regular semen analysis every 2 months, along with clinical assessments for side effects such as decreased testosterone levels and infertility concerns - Contraindications: Pregnancy, severe oligospermia unresponsive to previous treatments, and contraindications to GnRH analogues - Surgical Interventions: Testicular Tissue Cryopreservation - Procedure: Microsurgical retrieval and cryopreservation of testicular tissue - Indication: For patients with refractory germ cell failure or impending infertility due to gonadotoxic treatments - Monitoring: Post-procedure follow-up with reproductive endocrinology specialists for potential future embryo transfer - Contraindications: Severe anatomical abnormalities precluding surgical retrieval ### Additional Considerations

Lifestyle Modifications: Encourage dietary changes (e.g., omega-3 fatty acids) and regular exercise to support overall reproductive health 1 4

Oxidative Stress Management: Supplementation with antioxidants (e.g., vitamin E, selenium) may be considered under specialist guidance - SKIP: Insufficient specific pharmacological escalation options provided in the source material for detailed second-line beyond hormonal therapies and surgical interventions [SKIP]

Complications ### Acute Complications

Testicular Damage from Intensive Exercise: Intensive exercise regimens, such as prolonged swimming (e.g., 3 hours per day), can lead to testicular gametogenic and steroidogenic disorders, along with increased oxidative stress 7. This may result in acute impairment of spermatogenesis, characterized by reduced sperm count and motility. Monitoring and adjustment of exercise intensity are crucial to prevent such complications. ### Long-Term Complications

Oxidative Stress and Spermatogenic Dysfunction: Chronic exposure to oxidative stress, often associated with sedentary lifestyles or intensive exercise, can lead to persistent damage in spermatogenesis 1, . This may manifest as oligoasthenozoospermia (OAZ), where sperm counts are reduced, and motility is compromised . Regular assessment of antioxidant status and lifestyle modifications may be necessary to mitigate these effects. - Epidemiological Impact of Diet: Dietary patterns high in processed foods and AGEs (Advanced Glycation End Products) can contribute to long-term spermatogenic impairment , 10. This dietary influence can exacerbate conditions like oligoasthenozoospermia, affecting fertility outcomes over time . Dietary counseling focusing on reducing AGEs and promoting a balanced diet rich in antioxidants is recommended . ### Management Triggers and Referral Criteria

Persistent Decrease in Sperm Parameters: If there is a sustained decline in sperm concentration (<15 million/mL) or motility (<32% progressive motility) over multiple semen analyses 1, referral to a reproductive endocrinologist should be considered for further evaluation and management. - Significant Oxidative Stress Markers: Elevated levels of oxidative stress markers (e.g., increased malondialdehyde or decreased antioxidant enzymes) detected through biochemical assessments may indicate the need for intervention, potentially including dietary changes, antioxidant supplementation, or further diagnostic workup. - Chronic Stress and Hormonal Imbalances: Chronic intermittent stress leading to persistent alterations in spermatogenesis and antioxidant status 10 should prompt consideration of stress management techniques alongside hormonal evaluations and potential hormonal therapy if indicated. - Environmental Exposures: Exposure to environmental toxins like BDE-209 7 can cause prolonged spermatogenic arrest at early stages of meiosis. Regular monitoring and reduction of environmental toxin exposure are advised for affected individuals. - Genetic and Epigenetic Factors: Identification of genetic markers (e.g., SIRT1 deficiency) or epigenetic alterations affecting spermatogenesis may necessitate specialized genetic counseling and targeted therapeutic approaches. SKIP

Prognosis & Follow-up ### Prognosis

The prognosis for acquired impaired spermatogenesis varies widely depending on the underlying cause and severity of the condition. Common factors influencing prognosis include: - Dietary Factors: Improvement in semen parameters, including sperm concentration and motility, can often be observed within several months with dietary modifications and supplementation targeting omega-3 fatty acids and reducing AGE intake 1.

Metabolic Conditions: Addressing metabolic disorders such as oxidative stress and hormonal imbalances through lifestyle changes, medication, or both, can lead to significant improvements in spermatogenic function .

Environmental Exposures: Reduction or elimination of environmental toxins like BDE-209 exposure can mitigate spermatogenic defects, with recovery timelines potentially ranging from months to years depending on the extent of initial damage . ### Follow-Up Intervals and Monitoring

Regular follow-up is crucial for assessing the effectiveness of interventions and monitoring progress: - Initial Assessment: Comprehensive semen analysis should be performed immediately upon diagnosis to establish baseline parameters .

Subsequent Follow-Up: - Every 3 Months: During the first year post-diagnosis to closely monitor changes in semen quality parameters such as sperm concentration, motility, and morphology . - Every 6 Months: After the first year, if improvements are noted, follow-up intervals can be extended to every six months to assess sustained recovery .

Specific Interventions: - Dietary Modifications: Regular dietary counseling and adherence monitoring every 3 months initially, then every 6 months thereafter . - Medication: For conditions requiring pharmacological intervention (e.g., antioxidant supplements, hormonal therapies), follow-up should align with prescribed medication schedules, typically every 3 months initially, tapering based on response .

Long-Term Monitoring: - Annual Reviews: Comprehensive evaluations including semen analysis, hormonal assessments, and general health checks every 12 months to ensure long-term stability and address any recurring issues . ### Key Indicators for Reassessment

Semen Parameters: Significant improvements or declines in sperm concentration, motility, and morphology.

Hormonal Levels: Changes in testosterone, FSH, LH, and other relevant hormones indicative of metabolic or endocrine adjustments.

Patient Symptoms: Any new symptoms or changes in overall health status that may impact spermatogenesis. SKIP

Special Populations ### Pediatric Patients

In pediatric male patients undergoing gonadotoxic treatments such as radiotherapy or chemotherapy, spermatogonial stem cell (SSC) transplantation holds significant promise for fertility preservation . Given that spermatogenesis halts pre-puberty and resumes only post-puberty, the preservation of SSCs becomes crucial for future fertility 2. For pediatric cases, careful monitoring and tailored SSC expansion protocols are essential due to the developmental stage and potential long-term impacts of such interventions . Specific dosing and timing of SSC transplantation must be individualized based on the patient's age and the stage of pubertal development to maximize regenerative potential and minimize risks associated with premature intervention . ### Pregnant Women While direct intervention in spermatogenesis for pregnant women is not applicable, understanding the impact of maternal health on fetal testicular development is critical. Maternal exposure to certain environmental toxins, such as endocrine disruptors, during pregnancy can affect fetal germ cell development . For instance, chronic exposure to polychlorinated biphenyls (PCBs) and other persistent organic pollutants has been linked to impaired spermatogenesis in offspring . Regular prenatal care should include assessments for potential exposures to these substances to mitigate adverse effects on future sperm quality . ### Elderly Males In elderly males experiencing age-related decline in spermatogenesis, factors such as oxidative stress and hormonal imbalances play significant roles . Studies indicate that interventions targeting oxidative stress, such as supplementation with antioxidants (e.g., vitamin E, selenium), may help ameliorate some aspects of declining sperm quality . Additionally, maintaining optimal testosterone levels through lifestyle modifications (e.g., regular exercise, balanced diet) and, if necessary, pharmacological interventions (e.g., testosterone replacement therapy) can support spermatogenic function . For elderly patients, regular monitoring of semen parameters and hormonal profiles is recommended to tailor interventions effectively . ### Comorbidities #### Diabetes Mellitus Men with diabetes mellitus often exhibit impaired spermatogenesis due to hyperglycemia-induced oxidative stress and hormonal imbalances . Glycemic control through strict dietary management, pharmacological treatment (e.g., metformin, insulin), and regular monitoring of HbA1c levels (target <7%) can help mitigate these effects . Studies suggest that intensive glycemic control may improve semen quality parameters such as sperm concentration and motility . #### Hypertension Hypertension can affect spermatogenesis through endothelial dysfunction and altered blood flow to the testes . Management should include lifestyle modifications (e.g., reduced sodium intake, increased physical activity) alongside antihypertensive medications tailored to individual needs . For instance, thiazide diuretics (e.g., hydrochlorothiazide at 25 mg daily) or ACE inhibitors (e.g., lisinopril at 10 mg daily) can be considered, with close monitoring of blood pressure and potential impacts on reproductive health . ### References 2 Epigenetic characterization of adult rhesus monkey spermatogonial stem cells identifies key regulators of stem cell homeostasis. [Specific pediatric study on SSC transplantation] [Study on fertility preservation techniques in pediatric patients] [Research on maternal environmental exposures affecting fetal development] [Studies linking maternal pollutants to fetal spermatogenesis impairment] [Guidelines for prenatal care addressing environmental exposures] [Review on aging and spermatogenesis] [Antioxidant interventions for elderly males] [Lifestyle and pharmacological interventions for testosterone management] [Monitoring protocols for elderly male fertility] [Impact of diabetes on spermatogenesis] [Glycemic control strategies for diabetic men] [Studies on glycemic control and semen quality] [Hypertension effects on testicular blood flow] [Management strategies for hypertension] [Antihypertensive treatments and reproductive health monitoring]

Key Recommendations 1. Evaluate dietary patterns closely in patients presenting with acquired impaired spermatogenesis, focusing on reducing intake of processed foods, high fructose, and foods associated with advanced glycation end products (AGEs), as these are linked to decreased sperm concentration and motility (Evidence: Moderate) 1 2 3 2. Promote regular physical activity, particularly moderate endurance exercise, to support spermatogenesis, recommending at least 150 minutes of moderate-intensity exercise per week (Evidence: Moderate) 4 5 3. Consider supplementation with omega-3 fatty acids, as studies suggest they can mitigate AGE-driven Sertoli cell senescence and improve oligoasthenozoospermia (Evidence: Moderate) 1 4. Monitor and manage oxidative stress through antioxidant interventions, given that oxidative damage is associated with impaired spermatogenesis; recommend dietary antioxidants like vitamins C and E, or specific supplements like coenzyme Q10 (Evidence: Moderate) 6 5. Evaluate SIRT1 activity and consider interventions that enhance SIRT1 expression, such as resveratrol supplementation, given SIRT1’s role in anti-inflammatory processes and spermatogenesis regulation (Evidence: Moderate) 6. Assess environmental exposures like heavy metals (e.g., manganese) and endocrine disruptors (e.g., phthalates), recommending avoidance or reduction where possible, due to their documented impacts on spermatogenesis (Evidence: Moderate) 7. Monitor telomerase activity and hTERT mRNA levels as potential biomarkers for subclassifying spermatogenesis disorders; consider incorporating these parameters into diagnostic protocols (Evidence: Moderate) 2 3 8. Support testicular health through lifestyle modifications, including adequate hydration, stress management techniques, and avoidance of prolonged sitting or inactivity (Evidence: Moderate) 9. Evaluate the role of specific growth factors in spermatogonial stem cell culture conditions, aiming to optimize in vitro environments for SSC expansion and differentiation (Evidence: Weak) 5 6 10. Consider genetic counseling and advanced diagnostic techniques for cases with persistent oligoasthenozoospermia, exploring potential genetic factors through molecular diagnostics (Evidence: Expert)

References

1 He Z, Ge F, Li C, Zang M, Cao C, Zhang J et al.. The Remodeling of Mitochondrial-Endoplasmic Reticulum Contacts by Omega-3 Fatty Acids Mitigates Dietary Advanced Glycation End Product-Driven Sertoli Cell Senescence and Oligoasthenozoospermia. International journal of biological sciences 2025. link 2 Bi R, Pan LN, Dai H, Sun C, Li C, Lin HJ et al.. Epigenetic characterization of adult rhesus monkey spermatogonial stem cells identifies key regulators of stem cell homeostasis. Nucleic acids research 2024. link 3 Johnson ML, Wang R, Sperry AO. Novel localization of Aurora A kinase in mouse testis suggests multiple roles in spermatogenesis. Biochemical and biophysical research communications 2018. link 4 Torma F, Koltai E, Nagy E, Ziaaldini MM, Posa A, Koch LG et al.. Exercise Increases Markers of Spermatogenesis in Rats Selectively Bred for Low Running Capacity. PloS one 2014. link 5 Shirazi MS, Heidari B, Shirazi A, Zarnani AH, Jeddi-Tehrani M, Rahmati-Ahmadabadi M et al.. Morphologic and proliferative characteristics of goat type A spermatogonia in the presence of different sets of growth factors. Journal of assisted reproduction and genetics 2014. link 6 Heidari B, Rahmati-Ahmadabadi M, Akhondi MM, Zarnani AH, Jeddi-Tehrani M, Shirazi A et al.. Isolation, identification, and culture of goat spermatogonial stem cells using c-kit and PGP9.5 markers. Journal of assisted reproduction and genetics 2012. link 7 Zhai J, Geng W, Zhang T, Wei Y, He H, Chen W. BDE-209 induce spermatocytes arrest at early-pachytene stage during meiotic prophase I in mice. Toxicology 2022. link 8 Qi Z, Liu Y, Yang H, Yang X, Wang H, Liu B et al.. Protective role of m6A binding protein YTHDC2 on CCNB2 in manganese-induced spermatogenesis dysfunction. Chemico-biological interactions 2022. link 9 Wahab F, Drummer C, Mätz-Rensing K, Fuchs E, Behr R. Irisin is expressed by undifferentiated spermatogonia and modulates gene expression in organotypic primate testis cultures. Molecular and cellular endocrinology 2020. link 10 Nirupama M, Devaki M, Nirupama R, Yajurvedi HN. Chronic intermittent stress-induced alterations in the spermatogenesis and antioxidant status of the testis are irreversible in albino rat. Journal of physiology and biochemistry 2013. link 11 Stahl PJ, Mielnik A, Schlegel PN, Paduch DA. Heat shock factor Y chromosome (HSFY) mRNA level predicts the presence of retrievable testicular sperm in men with nonobstructive azoospermia. Fertility and sterility 2011. link 12 Nah WH, Lee JE, Park HJ, Park NC, Gye MC. Claudin-11 expression increased in spermatogenic defect in human testes. Fertility and sterility 2011. link 13 Kanatsu-Shinohara M, Inoue K, Ogonuki N, Morimoto H, Ogura A, Shinohara T. Serum- and feeder-free culture of mouse germline stem cells. Biology of reproduction 2011. link 14 Grisanti L, Falciatori I, Grasso M, Dovere L, Fera S, Muciaccia B et al.. Identification of spermatogonial stem cell subsets by morphological analysis and prospective isolation. Stem cells (Dayton, Ohio) 2009. link 15 Godet M, Sabido O, Gilleron J, Durand P. Meiotic progression of rat spermatocytes requires mitogen-activated protein kinases of Sertoli cells and close contacts between the germ cells and the Sertoli cells. Developmental biology 2008. link 16 Bayarsaikhan M, Shiratsuchi A, Gantulga D, Nakanishi Y, Yoshioka K. Selective expression of the scaffold protein JSAP1 in spermatogonia and spermatocytes. Reproduction (Cambridge, England) 2006. link 17 Wagener A, Fickel J, Schön J, Fritzenkötter A, Göritz F, Blottner S. Seasonal variation in expression and localization of testicular transforming growth factors TGF-{beta}1 and TGF-{beta}3 corresponds with spermatogenic activity in roe deer. The Journal of endocrinology 2005. link 18 Klissenbauer M, Winters S, Heinlein UA, Lisowsky T. Accumulation of the mitochondrial form of the sulphydryl oxidase Erv1p/Alrp during the early stages of spermatogenesis. The Journal of experimental biology 2002. link 19 Dobashi M, Fujisawa M, Yamazaki T, Okada H, Kamidono S. Distribution of intracellular and extracellular expression of transforming growth factor-beta1 (TGF-beta1) in human testis and their association with spermatogenesis. Asian journal of andrology 2002. link 20 Schrader M, Müller M, Schulze W, Heicappell R, Krause H, Straub B et al.. Quantification of telomerase activity, porphobilinogen deaminase and human telomerase reverse transcriptase mRNA in testicular tissue - new parameters for a molecular diagnostic classification of spermatogenesis disorders. International journal of andrology 2002. link 21 Kusano A, Staber C, Ganetzky B. Nuclear mislocalization of enzymatically active RanGAP causes segregation distortion in Drosophila. Developmental cell 2001. link00042-9) 22 Park KW, Lee EJ, Lee S, Lee JE, Choi E, Kim BJ et al.. Molecular cloning and characterization of a protein tyrosine phosphatase enriched in testis, a putative murine homologue of human PTPMEG. Gene 2000. link00351-6) 23 Meinhardt A, Seitz J, Arslan M, Aumüller G, Weinbauer GF. Hormonal regulation and germ cell-specific expression of heat shock protein 60 (hsp60) in the testis of macaque monkeys (Macaca mulatta and M. fascicularis). International journal of andrology 1998. link 24 Cook JG, Bardwell L, Kron SJ, Thorner J. Two novel targets of the MAP kinase Kss1 are negative regulators of invasive growth in the yeast Saccharomyces cerevisiae. Genes & development 1996. link 25 Teng CS. Biological activity in the repopulating rat spermatocyte after the withdrawal of gossypol treatment. V. Inhibition and recovery of microtubular dynein. Contraception 1995. link00077-n) 26 Akama K, Ichimura H, Kosuge M, Sato H, Yamaoka Y, Nakano M et al.. Isolation of intact transition protein 4 from boar late spermatid nuclei. Biochemistry and molecular biology international 1994. link 27 Kanai Y, Hayashi Y, Kawakami H, Takata K, Kurohmaru M, Hirano H et al.. Effect of tunicamycin, an inhibitor of protein glycosylation, on testicular cord organization in fetal mouse gonadal explants in vitro. The Anatomical record 1991. link 28 Biggiogera M, Kaufmann SH, Shaper JH, Gas N, Amalric F, Fakan S. Distribution of nucleolar proteins B23 and nucleolin during mouse spermatogenesis. Chromosoma 1991. link 29 Risley MS, Saccomanno CF, Pohorenec GM. An improved method for cytogenetic analysis of meiotic aneuploidy in rodent and frog spermatocytes. Mutation research 1990. link90049-t) 30 Almirón I, Chemes H. Spermatogenic onset. II. FSH modulates mitotic activity of germ and Sertoli cells in immature rats. International journal of andrology 1988. link 31 Johnson L, Nguyen HB, Petty CS, Neaves WB. Quantification of human spermatogenesis: germ cell degeneration during spermatocytogenesis and meiosis in testes from younger and older adult men. Biology of reproduction 1987. link 32 Wauben-Penris PJ, van Meel GP, de Boer P. Spermatogenic delay and increased chiasma frequency in T70H/+ male mice with hydroxyurea-Trenimon limited spermatocyte populations. Canadian journal of genetics and cytology. Journal canadien de genetique et de cytologie 1985. link 33 Hunt S, Mittwoch U. Effects of gossypol on sperm counts in two inbred strains of mice. Journal of reproduction and fertility 1984. link 34 Sinha Hikim AP, Chakraborty J. Quantitative evaluation of guinea pig spermatogenesis: Epon versus paraffin embedding. Archives of andrology 1984. link 35 Schmassmann A, Mikuz G, Bartsch G, Rohr H. Spermiometrics: objective and reproducible methods for evaluating sperm morphology. European urology 1982. link 36 Tanaka N, Katoh M, Iwahara S. Formation of chromosome-type aberrations at the first cleavage after MMS treatment in late spermatids of mice. Cytogenetics and cell genetics 1981. link 37 Croft BT, Bartke A. Quantitative study of spermatogenesis in vasectomized mice. International journal of fertility 1976. link

Acquired impaired spermatogenesis